Cargando…

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients

BACKGROUND/AIMS: We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance. METHODS: The indication for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Young Kul, Yeon, Jong Eun, Lee, Kwang Gyun, Jung, Eun Seok, Kim, Jeong Han, Kim, Ji Hoon, Seo, Yeon Seok, Yim, Hyung Joon, Um, Sun Ho, Ryu, Ho Sang, Byun, Kwan Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304672/ https://www.ncbi.nlm.nih.gov/pubmed/22310790 http://dx.doi.org/10.3350/kjhep.2011.17.4.261

Ejemplares similares

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
por: Lee, Han Ah, et al.
Publicado: (2016)

Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
por: Woo, Hyun Young, et al.
Publicado: (2014)

Hepatitis B Viral Surface Mutations in Patients with Adefovir Resistant Chronic Hepatitis B with A181T/V Polymerase Mutations
por: Kim, Jeong Han, et al.
Publicado: (2010)

Significance of Anti-HCV Signal-to-Cutoff Ratio in Predicting Hepatitis C Viremia
por: Seo, Yeon Seok, et al.
Publicado: (2009)

Clinical Significance of the Detection of Antinuclear Antibodies in Patients with Acute Hepatitis A
por: Seo, Yeon Seok, et al.
Publicado: (2011)

Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
por: Kim, Jihyun, et al.
Publicado: (2015)

Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation
por: Lee, Jae Geun, et al.
Publicado: (2015)

De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis
por: Lee, Han Ah, et al.
Publicado: (2021)

Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models
por: Kang, Seong Hee, et al.
Publicado: (2022)

Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus
por: Kim, Kang Mo, et al.
Publicado: (2005)

Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP
por: Lee, Young-Sun, et al.
Publicado: (2020)

Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
por: Gim, Jeong-An, et al.
Publicado: (2021)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Ahn, Young Eun, et al.
Publicado: (2021)

Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis
por: Gu, Dae Hoe, et al.
Publicado: (2018)

Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
por: Kim, Sehwa, et al.
Publicado: (2021)

Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
por: Kim, Tae Hyung, et al.
Publicado: (2022)

Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients
por: Lee, Ji Hun, et al.
Publicado: (2022)

Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery
por: Lee, Young-Sun, et al.
Publicado: (2019)

Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis
por: Lee, Young-Sun, et al.
Publicado: (2021)

Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
por: Kim, Tae Hyung, et al.
Publicado: (2021)

Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs
por: Larrat, Sylvie, et al.
Publicado: (2008)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
por: Wang, Zhao, et al.
Publicado: (2011)

Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease
por: Lee, Young-Sun, et al.
Publicado: (2020)

Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma
por: Lee, Han Ah, et al.
Publicado: (2021)

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients
por: Pereira-Gómez, Marianoel, et al.
Publicado: (2016)

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
por: Rodríguez, Manuel, et al.
Publicado: (2017)

Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores
por: Kim, Tae Hyung, et al.
Publicado: (2020)

Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study
por: Lee, Yoonseok, et al.
Publicado: (2023)

Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy
por: Wang, Changtai, et al.
Publicado: (2019)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1
por: Shin, Sang-Kyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ddmum06dtj10i223k06b94p14r